Pro-Israel Senator Lindsey Graham Dies at 71 After Brief Illness
Lindsey Graham, a senior Republican senator from South Carolina and a prominent pro-Israel figure in American politics, passed away at the age of 71 following a sudden and brief illness. His death was announced officially on his X (formerly Twitter) account and confirmed by a family statement expressing gratitude for prayers and requesting privacy during this difficult time.
Born on July 9, 1955, in Central, South Carolina, Graham came from a working-class family and was the first in his family to earn a college degree. He completed a bachelor's in psychology and a law degree at the University of South Carolina, which paved the way for his long legal and political career. Graham also served as a U.S. Air Force lawyer for 33 years, including active duty and reserve service, with deployments in Germany and legal roles during the Iraq and Afghanistan wars, retiring as a colonel in 2015.
Graham's political career began in the South Carolina House of Representatives, followed by service in the U.S. House from 1995 to 2003. He was elected to the U.S. Senate in 2002 and served for over two decades. He held key roles such as chairman of the Senate Judiciary Committee from 2019 to 2021 and was known as a hawkish voice advocating for active foreign policy and strong American interests.
Internationally, Graham was widely recognized for his staunch support of Israel, frequently visiting the country and fostering close strategic ties. His last visit was in February 2026, when he spoke at the David Kempinski Hotel in Tel Aviv, underscoring his deep involvement in U.S.-Israel relations. His passing leaves a significant void in the Republican Party and the U.S. Senate, with broad reactions across the international community.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.